Fondaparinux-associated Thrombocytopenia

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Heparin-induced thrombocytopenia (HIT) is a serious immune-mediated adverse drug reaction.
• It is characterized by thrombocytopenia and a high risk of thrombosis.
• HIT is typically associated with unfractionated heparin and low-molecular-weight heparin (LMWH).

Observation:

• Fondaparinux, a synthetic pentasaccharide, is structurally similar to heparin but has a lower reported incidence of HIT.
• This report details a rare instance of HIT occurring in a patient treated with fondaparinux.
• The patient presented with clinical signs and laboratory evidence consistent with HIT.

Findings:

• The case demonstrates that fondaparinux, despite its modified structure, can still precipitate HIT.
• Immune response against platelet factor 4 (PF4) complexed with the drug is the underlying mechanism.
• This finding underscores the need for vigilance even with alternative anticoagulants.

Implications:

• Clinicians should maintain a high index of suspicion for HIT in patients on fondaparinux presenting with thrombocytopenia.
• Alternative anticoagulation strategies may be necessary for patients with a history of HIT.
• Further research is warranted to fully elucidate the risk and mechanisms of fondaparinux-induced HIT.